Hebei Changshan Biochem Pharma
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of crude heparin, heparin raw materials, and heparin preparations for the treatment of cardiovascular and cerebrovascular diseases in China and internationally. The company offers crude heparin sodium, heparin sodium API, heparin sodium injections, low molecular weight heparin calcium i… Read more
Hebei Changshan Biochem Pharma (300255) - Net Assets
Latest net assets as of September 2025: CN¥1.48 Billion CNY
Based on the latest financial reports, Hebei Changshan Biochem Pharma (300255) has net assets worth CN¥1.48 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥4.66 Billion) and total liabilities (CN¥3.18 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.48 Billion |
| % of Total Assets | 31.74% |
| Annual Growth Rate | 19.12% |
| 5-Year Change | -46.18% |
| 10-Year Change | -2.26% |
| Growth Volatility | 85.29 |
Hebei Changshan Biochem Pharma - Net Assets Trend (2008–2024)
This chart illustrates how Hebei Changshan Biochem Pharma's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Hebei Changshan Biochem Pharma (2008–2024)
The table below shows the annual net assets of Hebei Changshan Biochem Pharma from 2008 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.54 Billion | -14.67% |
| 2023-12-31 | CN¥1.80 Billion | -41.07% |
| 2022-12-31 | CN¥3.05 Billion | -0.59% |
| 2021-12-31 | CN¥3.07 Billion | +7.67% |
| 2020-12-31 | CN¥2.85 Billion | +4.81% |
| 2019-12-31 | CN¥2.72 Billion | +7.90% |
| 2018-12-31 | CN¥2.52 Billion | +3.60% |
| 2017-12-31 | CN¥2.44 Billion | +6.38% |
| 2016-12-31 | CN¥2.29 Billion | +45.71% |
| 2015-12-31 | CN¥1.57 Billion | +10.11% |
| 2014-12-31 | CN¥1.43 Billion | +11.00% |
| 2013-12-31 | CN¥1.29 Billion | +14.20% |
| 2012-12-31 | CN¥1.13 Billion | +14.00% |
| 2011-12-31 | CN¥987.45 Million | +350.10% |
| 2010-12-31 | CN¥219.39 Million | +37.81% |
| 2009-12-31 | CN¥159.19 Million | +70.39% |
| 2008-12-31 | CN¥93.43 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Hebei Changshan Biochem Pharma's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 333.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥34.88 Million | 2.23% |
| Common Stock | CN¥919.06 Million | 58.83% |
| Other Components | CN¥608.32 Million | 38.94% |
| Total Equity | CN¥1.56 Billion | 100.00% |
Hebei Changshan Biochem Pharma Competitors by Market Cap
The table below lists competitors of Hebei Changshan Biochem Pharma ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Navinfo Co Ltd
SHE:002405
|
$3.07 Billion |
|
Patterson-UTI Energy Inc
NASDAQ:PTEN
|
$3.07 Billion |
|
Angel Yeast Co Ltd
SHG:600298
|
$3.08 Billion |
|
Petronas Chemicals Group Bhd
KLSE:5183
|
$3.08 Billion |
|
Jiangsu Yoke Technology Co Ltd
SHE:002409
|
$3.07 Billion |
|
Alliance Data Systems Corp.
LSE:0HCR
|
$3.07 Billion |
|
Rev Group Inc
NYSE:REVG
|
$3.07 Billion |
|
DeVry Education Group Inc
F:DVY
|
$3.06 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hebei Changshan Biochem Pharma's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,811,657,375 to 1,562,258,686, a change of -249,398,689 (-13.8%).
- Net loss of 249,477,721 reduced equity.
- Dividend payments of 119,928,863 reduced retained earnings.
- Other factors increased equity by 120,007,895.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-249.48 Million | -15.97% |
| Dividends Paid | CN¥119.93 Million | -7.68% |
| Other Changes | CN¥120.01 Million | +7.68% |
| Total Change | CN¥- | -13.77% |
Book Value vs Market Value Analysis
This analysis compares Hebei Changshan Biochem Pharma's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 23.78x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 218.26x to 23.78x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | CN¥0.18 | CN¥40.20 | x |
| 2009-12-31 | CN¥0.28 | CN¥40.20 | x |
| 2010-12-31 | CN¥0.35 | CN¥40.20 | x |
| 2011-12-31 | CN¥1.43 | CN¥40.20 | x |
| 2012-12-31 | CN¥1.33 | CN¥40.20 | x |
| 2013-12-31 | CN¥1.45 | CN¥40.20 | x |
| 2014-12-31 | CN¥1.59 | CN¥40.20 | x |
| 2015-12-31 | CN¥1.74 | CN¥40.20 | x |
| 2016-12-31 | CN¥2.54 | CN¥40.20 | x |
| 2017-12-31 | CN¥2.53 | CN¥40.20 | x |
| 2018-12-31 | CN¥2.69 | CN¥40.20 | x |
| 2019-12-31 | CN¥2.90 | CN¥40.20 | x |
| 2020-12-31 | CN¥3.10 | CN¥40.20 | x |
| 2021-12-31 | CN¥3.34 | CN¥40.20 | x |
| 2022-12-31 | CN¥3.33 | CN¥40.20 | x |
| 2023-12-31 | CN¥1.97 | CN¥40.20 | x |
| 2024-12-31 | CN¥1.69 | CN¥40.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hebei Changshan Biochem Pharma utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -15.97%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -24.20%
- • Asset Turnover: 0.23x
- • Equity Multiplier: 2.90x
- Recent ROE (-15.97%) is below the historical average (4.03%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 9.94% | 8.38% | 0.56x | 2.10x | CN¥-59.66K |
| 2009 | 22.84% | 14.33% | 0.95x | 1.67x | CN¥20.45 Million |
| 2010 | 27.44% | 12.90% | 1.08x | 1.96x | CN¥38.25 Million |
| 2011 | 7.17% | 16.72% | 0.36x | 1.20x | CN¥-27.94 Million |
| 2012 | 9.01% | 17.31% | 0.40x | 1.29x | CN¥-10.88 Million |
| 2013 | 9.37% | 16.35% | 0.43x | 1.34x | CN¥-7.75 Million |
| 2014 | 9.76% | 16.48% | 0.40x | 1.49x | CN¥-3.25 Million |
| 2015 | 10.33% | 17.06% | 0.39x | 1.54x | CN¥4.94 Million |
| 2016 | 7.87% | 15.69% | 0.36x | 1.41x | CN¥-47.40 Million |
| 2017 | 8.31% | 13.87% | 0.40x | 1.49x | CN¥-40.03 Million |
| 2018 | 5.57% | 8.47% | 0.43x | 1.53x | CN¥-111.29 Million |
| 2019 | 8.30% | 10.88% | 0.53x | 1.45x | CN¥-46.21 Million |
| 2020 | 8.88% | 10.70% | 0.52x | 1.61x | CN¥-31.92 Million |
| 2021 | 7.61% | 7.87% | 0.57x | 1.69x | CN¥-73.30 Million |
| 2022 | 0.57% | 0.75% | 0.39x | 1.97x | CN¥-288.29 Million |
| 2023 | -68.46% | -87.93% | 0.31x | 2.54x | CN¥-1.42 Billion |
| 2024 | -15.97% | -24.20% | 0.23x | 2.90x | CN¥-405.70 Million |
Industry Comparison
This section compares Hebei Changshan Biochem Pharma's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hebei Changshan Biochem Pharma (300255) | CN¥1.48 Billion | 9.94% | 2.15x | $3.07 Billion |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |